Concepedia

Author

Jane Robertson

AstraZeneca (United Kingdom)

Also Known As

J D Robertson, J Robertson, J-Y Douillard, J. D. Robertson, J. Robertson, J.D. ROBERTSON, J.D. Robertson, Jane D Robertson, Jane D. Robertson, Jane Robertson

80

Publications

2.8K

Citations

24

H-Index

51

Concepts

All Affiliations

AstraZeneca (United Kingdom)AstraZeneca (United States)Universidade de São PauloInstituto do Câncer do Estado de São PauloUniversity College London
JR

About

Jane Robertson is an author at AstraZeneca (United Kingdom) specializing in medicine, oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

13

14

932

2

Immunology

3

3

135

3

Health Sciences

2

2

125

4

Cell Biology

2

2

111

5

Obstetrics

2

2

451

Jane Robertson

×

27

Publications

2.6K

Citations

22

H-Index

YearCitations

Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid Tumors

Joachim Drevs, Patrizia Siegert, Michael Medinger,

Journal of Clinical Oncology

2007

302

Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy

Susan M. Domchek, Carol Aghajanian, Ronnie Shapira‐Frommer,

Gynecologic Oncology

2015

297

Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes

Darren Hodgson, Brian Dougherty, Zhongwu Lai,

British Journal of Cancer

2018

225

Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma

Jane Robertson, K.R. Nagesh, SimonN. Jowitt,

British Journal of Cancer

2000

206

Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III)

Hans‐Joachim Schmoll, David Cunningham, Alberto Sobrero,

Journal of Clinical Oncology

2012

206

Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety

Ursula A. Matulonis, Richard T. Penson, S. M. Domchek,

Annals of Oncology

2016

154

Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II)

Paulo M. Hoff, Andreas Hochhaus, Bernhard C. Pestalozzi,

Journal of Clinical Oncology

2012

152

Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization

Stéphanie Lheureux, Zhongwu Lai, Brian Dougherty,

Clinical Cancer Research

2017

150

Phase I and Pharmacokinetic Study of Daily Oral AZD2171, an Inhibitor of Vascular Endothelial Growth Factor Tyrosine Kinases, in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non–Small-Cell Lung Cancer: The National Cancer Institute of Canada Clinical Trials Group

Scott A. Laurie, Isabelle Gauthier, Andrew Arnold,

Journal of Clinical Oncology

2008

120

Dynamics of telomere shortening in neutrophils and T lymphocytes during ageing and the relationship to skewed X chromosome inactivation patterns

Jane Robertson, Rosemary E. Gale, Robert Wynn,

British Journal of Haematology

2000

96

Page 1